Oncotelic Therapeutics Highlights Peer鈥慠eviewed Publication Linking TGFB2 to Survival in Younger Pancreatic Cancer Patients
Oncotelic Therapeutics (OTCQB: OTLC) has highlighted a new peer-reviewed publication demonstrating the link between TGFB2 expression and survival rates in younger pancreatic cancer patients. The study revealed that high TGFB2 expression significantly reduced overall survival in patients under 65 years, with median survival of 17.9 months versus 66.9 months for those with low expression.
The research supports further evaluation of the company's investigational antisense drug OT-101 (trabedersen) as a TGFB2-targeted treatment for pancreatic ductal adenocarcinoma (PDAC). Clinical data from the OT-101 P001 PDAC study showed promising results, with a median overall survival of 12.7 months in a treated subset with low IL-6.
Oncotelic Therapeutics (OTCQB: OTLC) ha evidenziato una nuova pubblicazione peer-reviewed che dimostra il legame tra l'espressione di TGFB2 e i tassi di sopravvivenza nei pazienti pi霉 giovani con cancro al pancreas. Lo studio ha mostrato che un'elevata espressione di TGFB2 riduce significativamente la sopravvivenza globale nei pazienti sotto i 65 anni, con una sopravvivenza mediana di 17,9 mesi contro 66,9 mesi per coloro con bassa espressione.
La ricerca supporta una valutazione pi霉 approfondita del farmaco antisenso sperimentale dell'azienda, OT-101 (trabedersen), come trattamento mirato a TGFB2 per l'adenocarcinoma duttale pancreatico (PDAC). I dati clinici dello studio OT-101 P001 PDAC hanno mostrato risultati promettenti, con una sopravvivenza globale mediana di 12,7 mesi in un sottogruppo trattato con bassi livelli di IL-6.
Oncotelic Therapeutics (OTCQB: OTLC) ha destacado una nueva publicaci贸n revisada por pares que demuestra la relaci贸n entre la expresi贸n de TGFB2 y las tasas de supervivencia en pacientes j贸venes con c谩ncer de p谩ncreas. El estudio revel贸 que una alta expresi贸n de TGFB2 reduce significativamente la supervivencia global en pacientes menores de 65 a帽os, con una supervivencia media de 17,9 meses frente a 66,9 meses para aquellos con baja expresi贸n.
La investigaci贸n respalda una evaluaci贸n adicional del f谩rmaco antisense en investigaci贸n de la compa帽铆a, OT-101 (trabedersen), como tratamiento dirigido a TGFB2 para el adenocarcinoma ductal pancre谩tico (PDAC). Los datos cl铆nicos del estudio OT-101 P001 PDAC mostraron resultados prometedores, con una supervivencia global media de 12,7 meses en un subconjunto tratado con niveles bajos de IL-6.
Oncotelic Therapeutics (OTCQB: OTLC)电� 鞝婌潃 旆岇灔鞎� 頇橃瀽鞐愳劀 TGFB2 氚滍槃瓿� 靸濎〈鞙� 臧勳潣 鞐瓣磤靹�鞚� 鞛呾頃� 靸堧鞖� 霃欕 瓴�韱� 雲茧鞚� 臧曥“頄堨姷雼堧嫟. 鞐瓣惮鞐� 霐半ゴ氅� 65靹� 氙鸽 頇橃瀽鞐愳劀 雴掛潃 TGFB2 氚滍槃鞚� 鞝勳泊 靸濎〈鞙潉 鞙犾潣氙疙晿瓴� 臧愳唽鞁滌及鞙茧┌, 雮潃 氚滍槃 攴鸽９鞚� 欷戩暀 靸濎〈 旮瓣皠鞚� 17.9臧滌洈 雽� 66.9臧滌洈搿� 雮橅儉雮姷雼堧嫟.
鞚� 鞐瓣惮电� 旆岇灔甏� 靹犾晹(PDAC)鞚� 響滌爜鞙茧 頃樀鐢 TGFB2 旃橂鞝滌澑 須岇偓鞚� 鞁ろ棙鞝� 鞎堩嫲靹检姢 鞎诫 OT-101 (韸鸽澕氩犽嵃毳挫劶)鞚� 於旉皜 韽夑皜毳� 霋冯皼旃暕雼堧嫟. OT-101 P001 PDAC 鞛勳儊 雿办澊韯暗鐢 IL-6 靾橃箻臧� 雮潃 旃橂甑办棎靹� 欷戩暀 鞝勳泊 靸濎〈 旮瓣皠 12.7臧滌洈鞚措澕电� 鞙犽頃� 瓴瓣臣毳� 氤挫榾鞀惦媹雼�.
Oncotelic Therapeutics (OTCQB : OTLC) a mis en avant une nouvelle publication 茅valu茅e par des pairs d茅montrant le lien entre l'expression de TGFB2 et les taux de survie chez les patients plus jeunes atteints de cancer du pancr茅as. L'茅tude a r茅v茅l茅 qu'une expression 茅lev茅e de TGFB2 r茅duisait significativement la survie globale chez les patients de moins de 65 ans, avec une survie m茅diane de 17,9 mois contre 66,9 mois pour ceux pr茅sentant une faible expression.
Cette recherche soutient une 茅valuation plus approfondie du m茅dicament antisens exp茅rimental de la soci茅t茅, OT-101 (trabedersen), en tant que traitement ciblant TGFB2 pour l'ad茅nocarcinome canalaire pancr茅atique (PDAC). Les donn茅es cliniques de l'茅tude OT-101 P001 PDAC ont montr茅 des r茅sultats prometteurs, avec une survie globale m茅diane de 12,7 mois dans un sous-groupe trait茅 avec un faible taux d'IL-6.
Oncotelic Therapeutics (OTCQB: OTLC) hat eine neue peer-reviewed Ver枚ffentlichung hervorgehoben, die den Zusammenhang zwischen TGFB2-Expression und 脺berlebensraten bei j眉ngeren Bauchspeicheldr眉senkrebspatienten zeigt. Die Studie ergab, dass eine hohe TGFB2-Expression die Gesamt眉berlebenszeit bei Patienten unter 65 Jahren signifikant verringerte, mit einer medianen 脺berlebenszeit von 17,9 Monaten gegen眉ber 66,9 Monaten bei Patienten mit niedriger Expression.
Die Forschung unterst眉tzt eine weitere Bewertung des experimentellen Antisense-Medikaments des Unternehmens, OT-101 (Trabedersen), als TGFB2-zielgerichtete Behandlung f眉r das duktale Adenokarzinom der Bauchspeicheldr眉se (PDAC). Klinische Daten aus der OT-101 P001 PDAC-Studie zeigten vielversprechende Ergebnisse mit einer medianen Gesamt眉berlebenszeit von 12,7 Monaten in einer behandelten Untergruppe mit niedrigem IL-6.
- Study validates TGFB2 as a potential therapeutic target for pancreatic cancer treatment
- Clinical data supports OT-101's potential effectiveness in younger PDAC patients
- Company holds 45% ownership in GMP Biotechnology Limited, strengthening research capabilities
- Research provides method for patient stratification, enabling more precise clinical trials
- Five-year survival rate for PDAC remains low at only 12%
- PDAC incidence in younger adults is growing at concerning 4% annual rate
Data support further evaluation of investigational antisense OT鈥�101 (trabedersen) as a TGFB2鈥憈argeted approach in pancreatic ductal adenocarcinoma (PDAC).
AGOURA HILLS, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) (鈥淥ncotelic鈥� or the 鈥淐ompany鈥�), a clinical鈥憇tage biopharmaceutical company developing RNA鈥憈argeted and small鈥憁olecule therapeutics for cancer and rare diseases, today highlighted the publication of new translational research evaluating TGFB2 expression and promoter methylation as potential prognostic markers in pancreatic ductal adenocarcinoma (PDAC). The article, 鈥淭GFB2 Expression and Methylation Predict Overall Survival in Pancreatic Ductal Adenocarcinoma Patients,鈥� appears in the International Journal of Molecular Sciences (IJMS). The work involved investigators affiliated with Sapu Biosciences, LLC (鈥淪apu鈥�), a wholly owned subsidiary of GMP Biotechnology Limited (鈥淕MP Bio鈥�), of which Oncotelic holds a
Access the publication: DOI 10.3390/ijms26136357 (open access via IJMS).
Study Highlights
- Clinical data from the OT鈥�101 P001 PDAC study suggest that targeting TGFB2 merits additional evaluation in younger patients; in a treated subset characterized by low IL鈥�6, median OS was 12.7 months.鈥�
Investigator Commentary
鈥淭hese findings give clinicians a practical way to stratify patients and design more precise, age focused trials, an urgently needed step toward improving outcomes in this notoriously lethal disease. OT-101, TGFB2 targeted approach deserves testing in randomized clinical trials,鈥� said Professor鈥�Wasif鈥�Saif, MD, co author of the study and Director of Eisenberg Center for Translational Therapeutics and Co-director of gastro-enterology Oncology Program at Karmanos Cancer Institute. He further added. 鈥淥ur analysis shows that high TGFB2 expression was significantly associated with reduced overall survival (鈥淥S鈥�) in patients under 65 (TGFB2 high median vs. low median OS: 17.9 vs. 66.9 months) but not in older cohorts. Moreover, elevated TGFB2 methylation showed improved survival in younger patients (high methylation vs. low methylation median OS: 66.9 vs. 17.9 months). In addition, our clinical data from a Pancreatic Ductal Adenocarcinoma trial using OT-101, an antisense oligonucleotide targeting TGFB2, further supported these findings that young patients treated with OT-101 showed improved OS compared to untreated controls. TGFB2 is not just another biomarker; its expression clearly delineates a younger subset of pancreatic cancer patients who experience far poorer survival, and a patient population we are challenged more commonly over the last few years.鈥�
Additional Company Perspective
鈥淵ounger adults now represent the fastest-growing slice of PDAC incidence (鈮�4 % per year in the 15-34 bracket). Once diagnosed, their absolute outcomes remain grim鈥攆ive-year survival for all PDAC is only ~12 %. We see OT-101 playing an important therapeutic role in combating early onset PDAC,鈥� said Wen鈥慔an Chang, PhD, the lead bioinformatic scientist and Sr. Manager of Nanomedicine.鈥�
鈥淥ur PDAOAI knowledge platform helped our team efficiently assemble and interrogate the multi鈥憃mic and clinical datasets underlying this manuscript鈥攁n example of how we aim to accelerate therapeutic insight generation,鈥� added Scott Myers, Product Manager.鈥�
About OT鈥�101 (trabedersen)
OT鈥�101 is an investigational phosphorothioate antisense oligonucleotide designed to down鈥憆egulate transforming growth factor beta 2 (TGFB2), a cytokine implicated in tumor immune evasion, fibrosis, and resistance mechanisms across multiple solid tumors. OT鈥�101 has received Rare Pediatric Disease Designation for diffuse intrinsic pontine glioma (DIPG) via the Company鈥檚
About Oncotelic Therapeutics, Inc.
Originally founded as OXiGENE, Inc. in 1988 (New York) and reincorporated in Delaware (1992), the Company subsequently operated as Mateon Therapeutics, Inc. (2016) before adopting the name Oncotelic Therapeutics, Inc. in November 2020. Oncotelic leverages deep oncology drug鈥慸evelopment experience with a focus on high鈥憂eed and rare cancer indications. Programs within the Oncotelic/GMP Bio/Sapu ecosystem include: OT鈥�101 (TGFB2 antisense; DIPG and other indications), CA4P (melanoma), and OXi 4503 (acute myeloid leukemia), among others.鈥� Additional assets include AL鈥�101, an intranasal apomorphine program in-licensed in Q4 2021 and being assessed for several neurologic and sexual鈥慼ealth indications.鈥� For a fuller description of our pipeline and risk factors, please see our Form 10鈥慘 for the year ended December 31, 2024, filed April 15, 2025.
Additional Resources
- IJMS Publication: DOI 10.3390/ijms26136357 (open access).
- PDAOAI Public Discord: Community access to data sources used in manuscript development (non鈥慶ontrolled, research discussion environment; not intended for making investment or treatment decisions).鈥�
Oncotelic Cautionary Note on Forward鈥慙ooking Statements
This press release contains forward鈥憀ooking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this release other than statements of historical fact are forward鈥憀ooking and are based on current expectations, estimates, and projections about our business and future plans. In some cases, you can identify forward鈥憀ooking statements by terms such as 鈥渕ay,鈥� 鈥渨ill,鈥� 鈥渃ould,鈥� 鈥渨ould,鈥� 鈥渟hould,鈥� 鈥渆xpect,鈥� 鈥減lan,鈥� 鈥渁nticipate,鈥� 鈥渋ntend,鈥� 鈥渂elieve,鈥� 鈥渆stimate,鈥� 鈥減roject,鈥� 鈥渇orecast,鈥� 鈥減otential,鈥� 鈥渃ontinue,鈥� and similar expressions (including the negative of such terms).
Forward鈥憀ooking statements in this release include, without limitation: our plans, timelines, and priorities for the OT鈥�101 program in PDAC and other indications; potential biomarker鈥慸riven development strategies; the advancement, scope, timing, and results of current or future preclinical and clinical studies; regulatory interactions and potential approvals; development or commercialization of any product candidates within the Oncotelic/GMP Bio/Sapu ecosystem; the utility of our PDAOAI platform; future financings, strategic transactions, and/or public offerings involving our joint ventures or affiliates; and other statements that are not historical facts. Actual results may differ materially from those indicated by such forward鈥憀ooking statements as a result of various important factors, including, but not limited to: the inherent uncertainties of drug discovery and development; our ability to enroll patients and complete studies on expected timelines; whether preclinical or early clinical findings (including biomarker associations) will be replicated in larger, controlled trials; regulatory developments in the United States and other jurisdictions; competitive developments; our ability to obtain or maintain intellectual鈥憄roperty protection; our liquidity and access to capital; the performance of collaborators, suppliers, and manufacturers; and other risks described in our filings with the Securities and Exchange Commission (SEC), including the 鈥淩isk Factors鈥� section of our most recent Form 10鈥慘 and subsequent periodic reports.
Forward鈥憀ooking statements speak only as of the date of this press release, and we undertake no obligation to update or revise such statements, whether as a result of new information, future events, or otherwise, except as required by law.
Investor & Media Contact
Oncotelic Therapeutics, Inc.
Investor Relations
鈥� Source: Company materials and the IJMS publication, TGFB2 Expression and Methylation Predict Overall Survival in Pancreatic Ductal Adenocarcinoma Patients (Saif et al. 2025).
FAQ
What did Oncotelic Therapeutics (OTLC) reveal about TGFB2 and pancreatic cancer survival rates?
How effective is Oncotelic's OT-101 drug in treating pancreatic cancer?
What is the significance of TGFB2 methylation in pancreatic cancer treatment?
What is the current survival rate for pancreatic cancer according to OTLC's research?
How is pancreatic cancer affecting younger adults according to Oncotelic's findings?
